Renaissance Capital logo

Immunocore Holdings Priced, Nasdaq: IMCR

Phase 3 biotech developing T cell therapies for cancer and other diseases.

Industry: Health Care

Latest Trade: $48.71 +0.35 (+0.7%)

First Day Return: +66.2%

Return from IPO: +86.0%

Industry: Health Care

We are a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX -- Immune mobilizing monoclonal TCRs Against X disease -- designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. To date, we have dosed over 600 cancer patients with our ImmTAX product candidates, which we believe is the largest clinical data set of any bispecific in a solid tumor and any TCR therapeutic. Our clinical programs are being conducted with patients with a broad range of cancers including lung, bladder, gastric, head and neck and ovarian, among others. Our most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase 3 clinical trial in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.
more less
IPO News for Immunocore Holdings
more
IPO Data
IPO File Date 01/15/2021
Offer Price $26.00
Price Range $23.00 - $25.00
Offer Shares (mm) 9.9
Deal Size ($mm) $258
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/04/2021
Offer Price $26.00
Price Range $23.00 - $25.00
Offer Shares (mm) 9.9
Deal Size ($mm) $258
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Abingdon, United Kingdom
Founded 2007
Employees 291
Website www.immunocore.com